Lippi Giuseppe, Banfi Giuseppe, Franchini Massimo, Guidi Gian Cesare
Istituto di Chimica e Microscopia Clinica, Università di Verona, Verona, Italy.
J Sports Sci. 2008 Mar;26(5):441-5. doi: 10.1080/02640410701624556.
Doping in sports is commonplace. The prevention of harm to the athlete, the guarantee of fair play, and a level playing field for all competitors are the basis of the current anti-doping strategies. As healthcare systems are forced to allocate increasing resources to prevent and treat the prevailing pathologies worldwide, funding for anti-doping campaigns will necessarily be restricted. Ideally, additional resources should be devoted to increasing the number of athletes tested, the panels of tests used, and the frequency of out-of-competition controls. Since doping prevention cannot be considered a priority for most healthcare systems, such an approach is unaffordable and an alternative framework should be devised, focused primarily on harm reduction rather than fair play. The identification of abnormal deviations from reference values, regardless of pathological or artificial causes, would allow the athlete to be followed and tested using conventional laboratory tests, which are affordable to governments and healthcare systems and available to clinical laboratories. Although this strategy would not detect cheating, it would safeguard athletes' health.
体育界的兴奋剂使用现象屡见不鲜。防止对运动员造成伤害、确保公平竞争以及为所有参赛者提供公平的竞争环境,是当前反兴奋剂策略的基础。由于医疗保健系统被迫将越来越多的资源用于预防和治疗全球范围内普遍存在的疾病,反兴奋剂运动的资金必然会受到限制。理想情况下,应投入更多资源来增加接受检测的运动员数量、所使用的检测项目以及赛外检查的频率。由于对大多数医疗保健系统而言,预防兴奋剂使用并非优先事项,这种做法难以承受,因此应设计一个替代框架,主要侧重于减少危害而非公平竞争。识别与参考值的异常偏差,无论其原因是病理性的还是人为的,都可以让运动员接受常规实验室检测,并对其进行跟踪监测,这些检测对政府和医疗保健系统来说成本较低,临床实验室也能够进行。虽然这种策略无法检测出作弊行为,但它能保障运动员的健康。